Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NsGene AS

www.nsgene.com

Latest From Selectide Corp.

ArQule Takes the Drug Discovery Plunge

Over the past two-and-one-half years, ArQule's new management has refocused the once divided company, and repaired its reputation in the eyes of the financial community. That leadership also decided that ArQule can reach its growth potential only by moving away from a fee-for-services model and becoming a full-fledged drug discovery company. It's a transition that few companies have successfully managed, in part because of the tough balancing act required to build the requisite R&D infrastructure, while devoting sufficient resources to the near-term activity needed to build that infrastructure. ArQule will likely try to acquire biology-based companies to gain control over its own targets, but must deal with the valuation imbalance that still favors genomics/biology firms. But ArQule's management believes that its technology platform--as enhanced by the addition of predictive ADMET modeling--will boost its ability to process target into targets and thus its value.
BioPharmaceutical Strategy

Combinatorial Chemistry's Challenge

As large companies integrate combinatorial chemistry skills, small companies try to maintain their {raison d'être} with smaller "smarter" libraries, novel chemistries and informatics capabilities. They're also trying to build proprietary positions with drug leads of their own through 50-50 deals.
BioPharmaceutical Business Strategies

Dealmaking in 1995: The Theme is Product Breadth

If 1994's $61.3 billion in health care mergers seemed to put the health care industry on the road to a world of acquisition-hungry mega-merged drug, device and service companies, 1995, with its $63.7 billion in acquisition activity, has been the year of the unexpected: both in terms of what happened and what didn't.
BioPharmaceutical Medical Device

From Newton to Heisenberg--The New Physics of the Drug Industry

While the current wave of high profile drug industry deals recalls the heady days of 1980s consolidation, the motivations are quite different. Managed care is forcing companies to prize the efficient leveraging of assets, not critical mass. In today's drug industry, companies will manage for strategic diversity, juggling a number of different platforms at one time. Successful companies will by no means all have been successful using the same set of tools.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • NsGene AS
  • Senior Management
  • Teit E Johansen, PhD, Pres. & CEO
    Lars U Wahlberg, MD, PhD, EVP, COO
  • Contact Info
  • NsGene AS
    Phone: (45) 4460 8900
    Baltorpvej 154
    Ballerup, DK-2750
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register